HRTS250117P32670
- 0.00
- 0.000.00%
Tema GLP-1, Obesity & Cardiometabolic ETF Newsroom
Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025
Earnings Week Ahead: JPM, BAC, C, GS, TSM, UNH and More
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Key Deals This Week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and More
CMS Proposes 4.33% Increase for Medicare Advantage Plans
Weekly Buzz: CES Came and Brought the Pain? That's Unexpected
Wall Street Today: Labor Gains Hurt a Hurting Market
Catalyst Watch: Bank Earnings, Oil Updates, Powerhouse Conferences in Retail and Healthcare
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
UnitedHealth Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
First Earnings Show Beats are Back, December Jobs Climbed but Market Falls Friday | Live Stock
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460
Vertex Pharmaceuticals Analyst Ratings
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Cytokinetics Analyst Ratings
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
The sudden drop of Fast Retailing is a burden.
The Nikkei average has fallen for three consecutive days, closing down 414.69 yen at 39,190.40 yen (estimated Volume 1.7 billion 30 million shares), below the psychological threshold of 39,500 yen. The operating profit for Fast Retailing <9983> for the September-November 2024 period announced the previous day fell below market Financial Estimates, causing the company's stock to drop nearly 8% at one point. The decline widened toward the middle of the morning session, reaching as low as 39,166.05 yen. However, due to the consecutive declines, there was buying aimed at a rebound in the afternoon session.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far